JP2008532974A5 - - Google Patents

Download PDF

Info

Publication number
JP2008532974A5
JP2008532974A5 JP2008500172A JP2008500172A JP2008532974A5 JP 2008532974 A5 JP2008532974 A5 JP 2008532974A5 JP 2008500172 A JP2008500172 A JP 2008500172A JP 2008500172 A JP2008500172 A JP 2008500172A JP 2008532974 A5 JP2008532974 A5 JP 2008532974A5
Authority
JP
Japan
Prior art keywords
diabetes
pharmaceutically acceptable
acceptable salt
type
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008500172A
Other languages
English (en)
Japanese (ja)
Other versions
JP5091106B2 (ja
JP2008532974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/060418 external-priority patent/WO2006094933A1/en
Publication of JP2008532974A publication Critical patent/JP2008532974A/ja
Publication of JP2008532974A5 publication Critical patent/JP2008532974A5/ja
Application granted granted Critical
Publication of JP5091106B2 publication Critical patent/JP5091106B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008500172A 2005-03-08 2006-03-03 真性糖尿病の治療のためのロフルミラスト Expired - Fee Related JP5091106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05101772 2005-03-08
EP05101772.1 2005-03-08
PCT/EP2006/060418 WO2006094933A1 (en) 2005-03-08 2006-03-03 Roflumilast for the treatment of diabetes mellitus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012129982A Division JP5611275B2 (ja) 2005-03-08 2012-06-07 真性糖尿病の治療のためのロフルミラスト

Publications (3)

Publication Number Publication Date
JP2008532974A JP2008532974A (ja) 2008-08-21
JP2008532974A5 true JP2008532974A5 (OSRAM) 2009-04-30
JP5091106B2 JP5091106B2 (ja) 2012-12-05

Family

ID=34938922

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008500172A Expired - Fee Related JP5091106B2 (ja) 2005-03-08 2006-03-03 真性糖尿病の治療のためのロフルミラスト
JP2012129982A Expired - Fee Related JP5611275B2 (ja) 2005-03-08 2012-06-07 真性糖尿病の治療のためのロフルミラスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012129982A Expired - Fee Related JP5611275B2 (ja) 2005-03-08 2012-06-07 真性糖尿病の治療のためのロフルミラスト

Country Status (15)

Country Link
US (2) US8017633B2 (OSRAM)
EP (1) EP1874308A1 (OSRAM)
JP (2) JP5091106B2 (OSRAM)
KR (1) KR101302838B1 (OSRAM)
CN (2) CN102600144A (OSRAM)
AU (1) AU2006222060B2 (OSRAM)
BR (1) BRPI0609371A2 (OSRAM)
CA (1) CA2599376C (OSRAM)
EA (1) EA015382B1 (OSRAM)
IL (2) IL185277A (OSRAM)
MX (1) MX2007010560A (OSRAM)
NO (1) NO20074943L (OSRAM)
NZ (1) NZ560269A (OSRAM)
WO (1) WO2006094933A1 (OSRAM)
ZA (1) ZA200706294B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307589A (pt) 2002-02-11 2005-02-01 Antares Pharma Inc Dispositivo de injeção intradérmica
JP5216328B2 (ja) 2005-01-24 2013-06-19 アンタレス ファーマ インコーポレイテッド あらかじめ充填された針補助シリンジジェット式注射器
MX2007010560A (es) * 2005-03-08 2008-02-21 Nycomed Gmbh Roflumilast para el tratamiento de diabetes mellitus.
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
UA100497C2 (ru) * 2006-09-07 2013-01-10 Никомед Гмбх Комбинированное лечение сахарного диабета
EP2990067B1 (en) 2008-03-10 2019-09-04 Antares Pharma, Inc. Injector safety device
CN101548972B (zh) * 2008-04-03 2012-10-17 万特制药(海南)有限公司 一种含有瑞格列奈的固体药物组合物
JP5611208B2 (ja) 2008-08-05 2014-10-22 アンタレス・ファーマ・インコーポレーテッド 多数回服用量の注射装置
JP5732039B2 (ja) 2009-03-20 2015-06-10 アンタレス・ファーマ・インコーポレーテッド 危険有害性薬剤の注入システム
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
JP6165786B2 (ja) 2012-03-06 2017-07-19 アンタレス・ファーマ・インコーポレーテッド 離脱力特徴を備える充填シリンジ
AU2013203784A1 (en) 2012-04-06 2013-10-24 Kaushik J. Dave Needle assisted jet injection administration of testosterone compositions
US9364611B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
EP2953667B1 (en) 2013-02-11 2019-10-23 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
WO2014164786A1 (en) * 2013-03-11 2014-10-09 Madsen Patrick Dosage injector with pinion system
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
EP3165224A1 (en) * 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
US11267861B2 (en) 2016-04-19 2022-03-08 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB202306663D0 (en) * 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
JPS5869812A (ja) 1981-10-22 1983-04-26 Chugai Pharmaceut Co Ltd 血糖降下剤
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
IL87149A (en) 1987-07-20 1994-05-30 Merck & Co Inc 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9215633D0 (en) 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
EP0652868B1 (en) 1992-07-28 2004-11-10 Aventis Pharma Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE
CA2147180A1 (en) * 1992-10-15 1994-04-28 Gokhan S. Hotamisligil Treatment of insulin resistance in obesity linked type ii diabetes using antagonists to tnf-.alpha. function
HU220041B (hu) * 1993-07-02 2001-10-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények
EP0779292A4 (en) * 1994-08-29 1997-09-24 Yamanouchi Pharma Co Ltd NEW NAPHTHYRIDE DERIVATIVES AND MEDICAL COMPOSITIONS CONTAINING THEM
ATE233735T1 (de) * 1996-01-31 2003-03-15 Altana Pharma Ag Neue phenanthridine
DE19617864A1 (de) * 1996-04-23 1997-10-30 Schering Ag Neue chirale Phenyldihydrofuranone
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
JP2001516765A (ja) * 1997-09-12 2001-10-02 ヴォルフ ゲオルグ フォースマン 真性糖尿病及び肥満の治療のための組成物
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
WO2000042034A1 (en) 1999-01-15 2000-07-20 Byk Gulden Phenanthridine-n-oxides with pde-iv inhibiting activity
TR200101938T2 (tr) 1999-01-15 2001-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pde-ıv inhibe edici aktivitesi olan fenilfenantridinler.
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
AU3270301A (en) 1999-11-13 2001-05-30 Icos Corporation Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
EP1236725B1 (en) 1999-12-08 2004-03-10 Grelan Pharmaceutical Co., Ltd. Novel 1,8-naphthyridin-2(1h)-one derivatives
WO2001068621A1 (en) * 2000-03-13 2001-09-20 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclohexene derivatives useful as antagonists of the motilin receptor
AU2001239550A1 (en) * 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
JP2003534328A (ja) * 2000-05-25 2003-11-18 メルク フロスト カナダ アンド カンパニー フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤
HUP0300725A3 (en) 2000-08-11 2005-11-28 Pfizer Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
EP1308440B1 (en) * 2000-08-11 2009-05-06 Ono Pharmaceutical Co., Ltd. Piperidine derivatives and drugs containing these derivatives as the active ingredient
IL156958A0 (en) 2001-01-22 2004-02-08 Memory Pharm Corp Aniline derivatives useful as phosphodiesterase 4 inhibitors
CZ20031903A3 (cs) * 2001-01-31 2004-07-14 Pfizer Products Inc. Amidové deriváty thiazolyl-, oxazolyl-, pyrrolyl- a imidazolyl karboxylových kyselin užitečné jako inhibitory isozymů PDE4
ES2248231T3 (es) * 2001-01-31 2006-03-16 Pfizer Products Inc. Derivados de eteres utiles como inhibidores de las isozimas pde4.
EA200300836A1 (ru) 2001-02-15 2004-02-26 Алтана Фарма Аг Производные фталазинон-пиперидина в качестве ингибиторов pde4
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
ES2319517T3 (es) * 2002-05-28 2009-05-08 Nycomed Gmbh Preparacion farmaceutica aplicable topicamente.
AU2003253130A1 (en) * 2002-08-19 2004-03-03 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
WO2004098597A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and shuil-1r ii
WO2004098596A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
WO2004098598A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098595A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
CA2525946C (en) * 2003-05-22 2013-01-29 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
WO2005020926A2 (en) * 2003-08-28 2005-03-10 Pharmacia Corporation Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
WO2005023253A1 (en) * 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
CA2542277A1 (en) 2003-10-21 2005-05-12 Pharmacia Corporation Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith
TW200539867A (en) 2004-04-13 2005-12-16 Arena Pharm Inc Human g protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders
MX2007010560A (es) * 2005-03-08 2008-02-21 Nycomed Gmbh Roflumilast para el tratamiento de diabetes mellitus.

Similar Documents

Publication Publication Date Title
JP2008532974A5 (OSRAM)
JP2010529203A5 (OSRAM)
JP2008543776A5 (OSRAM)
CL2007002347A1 (es) Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm
JP2009529541A5 (OSRAM)
JP2008528441A5 (OSRAM)
JP2009514837A5 (OSRAM)
JP2009501177A5 (OSRAM)
JP2009501178A5 (OSRAM)
WO2015200078A8 (en) Fatty acids and their use in conjugation to biomolecules
NZ598323A (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
JP2008007519A5 (OSRAM)
RU2010120808A (ru) Производное амина, обладающее активностью антагониста npy y5 рецептора, и его применение
EP1726580A4 (en) AMINOPHNYLPROPANO ACID DERIVATIVE
WO2009042922A3 (en) Peptide-peptidase inhibitor conjugates and methods of making and using same
WO2007104789A3 (en) Amylin derivatives
JP2009514835A5 (OSRAM)
JP2008531520A5 (OSRAM)
JP2009538898A5 (OSRAM)
RU2012150108A (ru) Аналоги глюкагоноподобного пептида-1 и их применение
BRPI0407180A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto
NZ594244A (en) Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof
RU2019111421A (ru) Способы лечения острого повреждения почек
RU2015142255A (ru) Фармацевтическое комбинированное лекарственное средство
JP2018502135A5 (OSRAM)